Biovitrum study to target glaucoma

December 1, 2006

Biovitrum, a Stockholm-based biopharmaceutical company, has initiated a clinical phase II study with the candidate drug BVT.28949, a 5-HT2A antagonist for treating glaucoma.

Biovitrum, a Stockholm-based biopharmaceutical company, has initiated a clinical phase II study with the candidate drug BVT.28949, a 5-HT2A antagonist for treating glaucoma.

The placebo-controlled study of 150 patients with elevated IOP will be conducted at several clinics in Sweden and the Ukraine next spring. Results are expected in mid-2007.

The company believes that BVT.28949 reduces IOP by stimulating the outflow of aqueous humor through the trabecular meshwork, unlike prostaglandins. The eye drops could function alone or in combination with existing products, according to the company.

Related Content:

News | Pharmacy